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The median dose in bladder with XB vs. Ir192 was: 2cc 
64.01 vs. 69.9%, V50 7.2 vs. 12.6Gy, V35 15.2 vs. 28.1. In 
rectum XB vs. I192 was: D 2cc 65.17% vs. 67.7%, V50 7.9 
vs. 10.9Gy, V35 16.7 vs. 31.8Gy. In sigmoid XB vs. I192 
was: D 50% vs. 58.0%, V50 8.6 vs. 16.2Gy, V35 21.1 vs. 
37.5Gy.  
The median follow-up was 21 months (range 5 - 36 
months). 
In group 1, acute vaginal mucositis (G1) was observed in 
32.91% of the patients, GI toxicity (G1) in 5.41% and GU 
toxicity (G1) in 8.11%. 
In group 2, we observed acute vaginal mucositis G1 in 
34.09% of the patients and G2 in 4.55%, GI toxicity (G1) 
occurred in 6.52% and GU toxicity (G1) was present in 
13.04%. There was no grade 3 or greater toxicity in any of 
the groups. Late toxicity was observed in only 4 patients: 
Mucositis (G1) in 3 patients, GI (G1) in 2 and GU toxicity 
(G1) in 3 patients. 
Conclusion 
The dose received by the organs at risk with the XB is less 
compared to Ir192, with a good coverage of the PTV. The 
greater toxicity was observed immediately after the 
treatment was finished with an important reduction of the 
symptoms after 6 months. This technique shows excellent 
results as for toxicity. 
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Purpose or Objective 
To analyse the outcomes in terms of toxicity and survival 
analysis after treatment with Xoft Axxent Electronic 
Brachytherapy (XB) in postsurgical gynaecologic cancer 
patients treated at our medical centre.  
Material and Methods 
Prospective study in which we selected 140 patients that 
received treatment with Xoft Axxent Electronic 
Brachytherapy administered twice a week after 
gynaecologic cancer surgery, with 3D planification. The 
patients were selected from September 2015 to July 2018. 
They were divided in two groups: Group 1 (91/140) 
considered high risk and group 2 (49/140) intermediate 
risk. Group 1 received external beam radiotherapy (46Gy) 
followed by XB (15Gy in 5Gy fractions) and group 2 
received exclusive XB (25Gy in 5Gy fractions). We 
analyzed the median dose in bladder, rectum and sigmoid 
D2cc with XB. The vaginal mucosa, gastrointestinal (GI) 
and genitourinary (GU) toxicities were analyzed with the 
Common Terminology Criteria for Adverse Events (CTCAE 
4.0) scale. We built a Kaplan-Meier  curve to estimate the 
survival over time of follow-up. 
Results 
The median follow-up was 20 months (range 3 - 36 
months). Of all the patients treated, 87.14% were 
endometrial cancer patients, 7.86% cervical cancer, 2.86% 
vaginal cancer and 2.14% were vaginal recurrences.  The 
median dose in bladder with XB was D2cc: 12,01Gy. In 
rectum median D2cc was 11,78Gy. In sigmoid median D2cc 
was 9,24Gy.  In terms of toxicity, acute vaginal mucositis 
(G1) was observed in 21.29% of the patients and G2 in 
1.43%, GI toxicity (G1) occurred in 4.28% and GU toxicity 
(G1) in 7.14%. There was no grade 3 or greater toxicity in 
any of the groups. At 6 months follow-up, all of the 
patients were asymptomatic.  As for survival, 4 patients 
have died during the follow-up, 2 of them showed systemic 
progression and the other 2 had synchronous tumor. The 
Kaplan Meier results, show that at 2 years follow-up, 95% 
of the patient are going to be alive. We have estimated 





The electronic brachytherapy is an alternative to high 
dose-rate brachytherapy. The XB obtains goos coverage of 
PTV with lower doses in organs at risk.  The greater 
toxicity was observed immediately after the treatment 
was finished with an important reduction of the symptoms 
after 6 months. It also shows an excellent rate of overall 
survival and progression frees disease. 
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Purpose or Objective 
To assess the outcome of salvage brachytherapy for oral 
and oropharyngeal squamous cell carcinoma in previously 
irradiated areas. 
Material and Methods 
This is a retrospective study of 25 patients treated at the 
Centre Léon Bérard between 1997 and 2016 for primary 
(21) or recurrent (4) oral or oropharyngeal SCC in a 
previously irradiated area. Fifteen patients were treated 
with salvage brachytherapy alone, while 10 patients also 
received external radiotherapy. The median time between 
the first and the second irradiation was 56 months (range, 
10-212 months). All but three patients had surgical 
resection and four patients received chemotherapy. The 
median brachytherapy dose was 45 Gy (range, 15-64 Gy) 
for a median total dose of 57 Gy (range, 40-70 Gy). Patient 
age, BMI, tumor stage, radiotherapy dose and time 
between the first treatment and recurrence were 
analyzed as prognostic factors. 
Results 
The median overall survival was 16 months. Patients with 
less advanced (T1) tumors survived significantly longer (27 
vs 14.5 months, p = 0.046). Five patients experienced a 
local recurrence, only one of which had been treated with 
a total dose greater than 60 Gy. In multivariate analysis, 
the risk of death was found to be 80% lower in patients 
who had received more than 60 Gy (p = 0.072). There was 
four grade 3 acute toxicities and no grade 3 or greater late 
toxicities. 








Salvage brachytherapy may offer a curative option for 
selected patients with an acceptable risk of severe 
toxicity for the treatment of primary or recurrent tumor 
in a previously irradiated area. 
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Purpose or Objective 
To present the results of a patient therapeutic approach 
using a second course of Interventional Radiotherapy 
(Brachytherapy) in a setting of patients with local 
recurrence of uveal melanoma.  
Material and Methods 
Patients who had already undergone ocular brachytherapy 
at IOC (Interventional Oncology Center) of the “Gemelli 
ART” (Advanced Radiation Therapy) of Rome were 
considered. In this group, five patients with a local 
recurrence that received a second course of treatment 
with a plaque were included in our analysis. The 
reirradiation was performed with a plaque of Ruthenium-
106 (dose prescribed to the apex 100 Gy) or of Iodine-125 
(dose prescribed to the apex 85Gy).  
Results 
All patients were in the first time treated with Ruthenium 
106 plaque; the reirradiation was performed with 
Ruthenium 106 plaque in three cases and with Iodine in 
the remaining two cases The mean time between the first 
and the second plaque was 56.8 months (range 25-93 
months). After a median follow-up of 44.2 months (range 
26-65 months) from retreatment the local tumor control 
rate was 100% and there was no patient who underwent 
secondary enucleation due to retreatment failure. Distant 
metastasis occurred in one patient after 6 months from 
retreatment. All patients evolved a worsening of the visual 
acuity (median visual acuity was 0.42 at time of 
recurrence and declined to 0.24 at the most recent follow-
up); cataract occurred in two cases, no patient developed 
scleral necrosis.  
Conclusion 
In well selected cases a retreatment strategy with plaque 
may offer a high probability of tumor control and organ 
preservation with a worsening in the visual acuity. 
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